HU

Hugel, Inc.

Global provider of medical aesthetic solutions like botulinum toxin and HA fillers.

145020 | KO

Overview

Corporate Details

ISIN(s):
KR7145020004
LEI:
Country:
South Korea
Address:
강원특별자치도 춘천시 동내면 거두단지1길 23 -, 춘천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hugel, Inc. is a global biopharmaceutical company specializing in the medical aesthetics and therapeutics market. The company develops, manufactures, and sells a range of products, including its flagship botulinum toxin, hyaluronic acid (HA) fillers, skin boosters, and cosmetic threads. Recognized for its advanced technology, Hugel is a leading provider in the aesthetics field, having expanded its presence from its base in South Korea to major international markets such as the USA, Europe, and China. The company focuses on creating value in medical aesthetics by providing high-quality, scientifically-backed solutions for medical professionals and consumers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Board/Management Information
대표집행임원변경
Korean 12.6 KB
2025-09-15 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.7 KB
2025-09-12 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.1 KB
2025-08-29 00:00
Related Party Transaction
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 8.6 KB
2025-08-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-14 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 4.5 MB
2025-08-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-08-07 00:00
Regulatory News Service
풍문또는보도에대한해명(미확정)
Korean 11.8 KB
2025-08-06 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.7 KB
2025-08-06 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.1 KB
2025-08-06 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 34.5 KB
2025-08-06 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.2 KB

Automate Your Workflow. Get a real-time feed of all Hugel, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hugel, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hugel, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.